Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
暂无分享,去创建一个
Graeme Currie | George Kitis | P. Marcellin | Z. Goodman | S. Lim | M. Rizzetto | G. Kitis | Ting Chang | E Jenny Heathcote | Ting-Tsung Chang | Zachary Goodman | S. Arterburn | E. Heathcote | S. Hadziyannis | E. Heathcote | G. Currie | Mario Rizzetto | Patrick Marcellin | Seng Gee Lim | Stephanos J Hadziyannis | Shelly Xiong | Sarah Arterburn | Nicolaos C Tassopoulos | Jia Ma | Carol L Brosgart | S. Xiong | C. Brosgart | N. Tassopoulos | Seng‐Gee Lim | Jia Ma
[1] Neil Kaplowitz,et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.
[2] S. Hadziyannis,et al. Efficacy of long‐term lamivudine monotherapy in patients with hepatitis B e antigen–negative chronic hepatitis B , 2000, Hepatology.
[3] Pietro Andreone,et al. Clinical outcome of HBeAg‐negative chronic hepatitis B in relation to virological response to lamivudine , 2004, Hepatology.
[5] P. Marcellin,et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. , 2004, The New England journal of medicine.
[6] A. Lok,et al. World‐wide epidemiology of HBeAg‐negative chronic hepatitis B and associated precore and core promoter variants , 2002, Journal of viral hepatitis.
[7] Angeline Bartholomeusz,et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. , 2003, Gastroenterology.
[8] A. Makris,et al. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. , 1990, Journal of hepatology.
[9] M. Wulfsohn,et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. , 2003, The New England journal of medicine.
[10] D. Richman. The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B , 2000, Hepatology.
[11] S. Hadziyannis,et al. The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis B , 2001 .
[12] Brunetto. Identification of HBV variants which cannot produce pre-core derived HBeAg and may be responsible for severe hepatitis , 1989 .
[13] A. Lok,et al. Treatment of hepatitis B , 2002, Journal of Gastroenterology.
[14] T. Santantonio,et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. , 2000, Journal of hepatology.
[15] M. Wulfsohn,et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B , 2003, Hepatology.
[16] D. Vassilopoulos,et al. Hepatitis B e antigen–negative chronic hepatitis B , 2001, Hepatology.
[17] A. Morabito,et al. A randomized, controlled trial of a 24‐month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum , 1997, Hepatology.